



European Campus of City-Universities - EC²U

Work Package 4 - GLADE Virtual Institute Half Day Conference

Cancer: prevention, prognosis and treatment.

Monday June 27th 2022, 10 am - 13:30 pm (CET)

Registration: <https://bit.ly/3rPCKcd>.

Theme: GLADE

Time: Jun 27, 2022 10:00 PM m. Madrid

Join Zoom meeting

https://usal-es.zoom.us/j/85236605931?pwd=8o_7UMgkPJ9ZjpC15m500Xn_X9kzqF.1

Meeting ID: 852 3660 5931

Access code: 438256

Join via SIP

85236605931@zoomcrc.com

The Virtual Institute for Good Health and Well-being (GLADE), developed within the EC2U alliance of European universities, organizes a series of half-day conferences for all members of the 7 EC²U universities: Salamanca, Coimbra, Poitiers, Pavia, Iasi, Turku and Jena.

GLADE conferences are intended to strengthen academic and professional links between researchers, academic staff and students from the 7 EC²U Universities.

This is a great opportunity to reveal interests, results, concerns and research proposals in different areas of knowledge.

University of Salamanca is organizing a series of virtual conferences on “Cancer (prevention, prognosis, treatment)” on the 27th (10:00-13:00).

You will have the opportunity to connect with professionals in your field of interest, exchange research ideas, and participate in new projects.

To register: Cancer (prevention, prognosis, treatment): <https://bit.ly/3rPCKcd>

#ec2ualliance EC2U Alliance

@UAICdiniASI | @unijena | @univpoitiers | @univdecoimbra | @universidaddesalamanca | @uniturku | @universitapavia

10:00 am. Opening
10:15 am. High frequency of small neoplastic B-cell clones in hospitalized COVID-19 patients: association with severity of infection. Julia Almeida .Faculty of Medicine. University of Salamanca.
10:30 am. <i>Mechanical determinants of T cell activation and leukemia.</i> Miguel Vicente-Manzanares. Cancer Research Center. University of Salamanca.
10:45 am. Development of new therapies against glioblastoma based on specific protein functions. Arantxa Tabernero. Faculty of Biology and Institute of Neuroscience Castilla y León. University of Salamanca.
11:00 am. Mass spectrometry for the detection of minimal residual disease (MRD) in multiple myeloma. Noemi Puig. University Hospital of Salamanca.
11:15 am. Determinants of breast and cervical cancer screening within and outside target groups in Portugal. Carlota Quintal. University of Coimbra

11:30 am. . **Genomic profiling of Myeloproliferative Neoplasms.**
Ilaria Carola Casetti. University Hospital of Pavia.

12:00 pm. **Cancer therapy: from nature and bench to the bedside.**
Ángela P. Hernández. Faculty of Pharmacy. University of Salamanca.

12:15 pm. **Molecular mechanisms of drug resistance in Hematological Neoplasias
- implications in prognosis and therapeutic failure.**
Ana Bela Sarmiento Ribeiro. Faculty of Medicine. University of Coimbra.

12:30 pm. **New therapies in HER2 positive breast cancer: Novel ADCs and
mechanisms of resistance.**
Elena Díaz-Rodríguez. Faculty of Medicine and Cancer Research Center. University of Salamanca.

12: 45 pm **Intermediate molecular phenotypes to identify heritability and
markers of anthracycline-induced cardiotoxicity risk.**
Jesús Pérez Losada. Cancer Research Center. University of Salamanca.

13:00 h. **Enhancing the efficacy of immunotherapy in NSCLC by vascular
modulation.**
José M. Muñoz-Félix. Faculty of Biology. University of Salamanca.

13:15 h. Closing